Estela Rojas

Estela Rojas

Auto-generated profile, based on publicly available information

Estela Rojas

Department of Lymphoma and Myeloma University of Texas MD Anderson Cancer Center Houston Texas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
The activated B cell (ABC) subset of diffuse large B-cell lymphoma (DLBCL) is characterized by chronic B-cell receptor signaling and associated with poor outcomes when treated with standard therapy. In ABC-DLBCL, MALT1 is a core enzyme that is constitutively activated by stimulation of the B-cell receptor or gain-of-function mutations in upstream components of the signaling pathway, making it an attractive therapeutic target. We discovered a novel small-molecule inhibitor, ABBV-MALT1, that potently shuts down B-cell signaling selectively in ABC-DLBCL preclinical models leading to potent cell growth and xenograft inhibition. We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.

24 June 2026 in Blood Cancer Discovery
Verified
Journal Article
Open access
HYHaopeng Yang
Haopeng Yang
KAKotaro Arita
Kotaro Arita
KBKevin Bowman
Kevin Bowman
DCDai Chihara
Dai Chihara
JHJared Henderson
Jared Henderson
Michael GreenMichael Green
Michael Green
Large B-cell lymphomas (LBCL) are a clinically and molecularly diverse group of malignancies with a rapidly evolving therapeutic landscape that has introduced new areas of clinical need, such as post-CD19 chimeric antigen receptor T (CART19) progression. Patient-derived xenograft (PDX) models are an important tool for mechanistic studies and preclinical evaluation of new therapies and can be generated from a variety of clinical contexts that capture tumor-intrinsic resistance mechanisms. We therefore undertook a comprehensive effort to generate PDX models that encompass the molecular landscape of LBCLs and include important clinical scenarios for new drug development. Here, we describe the first 48 models within this publicly available repository, capturing the transcriptional and genetic subsets of LBCL. These models also include 23 generated from post-CART19 progression patient biopsies, which reproduce patterns of progression driven by CD19 mutation or expression loss, as well as tumor cell–intrinsic CART19 resistance that we validated in vivo. Significance: Here, we describe X-LYMPH (Xenografts of Lymphoma), a publicly available and molecularly annotated PDX repository that captures the heterogeneity of LBCL. X-LYMPH includes models of CAR T-cell resistance, providing a shared foundation for mechanistic research and therapeutic development for lymphomas.

17 June 2026
Verified
Other
Open access
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
Whole proteomic analysis of ABBV-MALT1 in OCI-LY3

2 July 2024
Verified
Other
Open access
PDF file
JPJoshua P. Plotnik
Joshua P. Plotnik
ARAdam E. Richardson
Adam E. Richardson
HYHaopeng Yang
Haopeng Yang
EREstela Rojas
Estela Rojas
VBVelitchka Bontcheva
Velitchka Bontcheva
WPWilliam N. Pappano
William N. Pappano
MALT1 and BCL2 inhibition do not antagonize each other in monotherapy sensitive patient derived xenografts